CLINICAL_TRIALS
ClinicalTrials.gov record update
Evaluation of Vildagliptin (Galvus®) as add-on to Insulin in Residual β-cell Function and Inflammatory Markers in New-onset Type 1 Diabetes Mellitus.
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT01559025
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:35:42.667716+00:00
- Published At
- 2014-05-14T00:00:00+00:00
- Record Updated At
- 2014-05-14
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Type 1 Diabetes", "Insulin Dependent Diabetes", "Juvenile Onset Diabetes Mellitus", "Autoimmune Diabetes"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2014-05-14"- protocolSection.identificationModule.nctId
"NCT01559025"- protocolSection.identificationModule.officialTitle
"Evaluation of Vildagliptin (Galvus\u00ae) as add-on to Insulin in Residual \u03b2-cell Function and Inflammatory Markers in New-onset Type 1 Diabetes Mellitus."- protocolSection.statusModule.overallStatus
"UNKNOWN"- protocolSection.designModule.phases
["PHASE3"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.